Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


Adjunctive atorvastatin reduces cardiac dysfunction in patients with anthracycline-treated lymphoma

Written by | 8 Aug 2023

Adjunctive therapy with atorvastatin appears to reduce the proportion of patients with lymphoma who are being treated with anthracyclines and who also develop cardiac dysfunction. The findings were… read more.

New data informs treatment of blood cancer during pregnancy

Written by | 6 Jun 2023

Today, Blood Advances published a study revealing that patients with relapsed/refractory (r/r) lymphoma during pregnancy experienced a progression-free survival rate of 24% and an overall survival rate of 83%…. read more.

FDA grants Brukinsa accelerated approval in relapsed or refractory marginal zone lymphoma – BeiGene

Written by | 2 Feb 2022

BeiGene, Ltd. announced that Brukinsa (zanubrutinib) has received accelerated approval from the FDA for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL)… read more.

Health Canada approves Brukinsa to treat Mantle Cell Lymphoma – BeiGene

Written by | 4 Aug 2021

BeiGene, Ltd. a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, announced that Brukinsa (zanubrutinib) has… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.